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The trial compared three physiotherapy approaches: manual or exercise therapy compared with a single session 
of physiotherapy education (SSPT) for people with osteoporotic vertebral fracture(s). At 1 year, there were no 
statistically significant differences between the groups meaning there is inadequate evidence to support 
manual or exercise therapy. 
Introduction  
To evaluate the clinical and cost-effectiveness of different physiotherapy approaches for people with 
osteoporotic vertebral fracture(s) (OVF). 
Methods 
Prospective, multicentre, adaptive, three-arm randomised controlled trial. Six hundred fifteen adults with back pain, 
osteoporosis, and at least 1 OVF participated. Interventions: 7 individual physiotherapy sessions over 12 weeks 
focused on either manual therapy or home exercise compared with a single session of physiotherapy education 
(SSPT). The co-primary outcomes were quality of life and back muscle endurance measured by the QUALEFFO-41 
and timed loaded standing (TLS) test at 12 months. 
Results  
At 12 months, there were no statistically significant differences between groups. Mean QUALEFFO-41: − 1.3 
(exercise), − 0.15 (manual), and − 1.2 (SSPT), a mean difference of − 0.2 (95% CI, − 3.2 to 1.6) for exercise and 1.3 
(95% CI, − 1.8 to 2.9) for manual therapy. Mean TLS: 9.8 s (exercise), 13.6 s (manual), and 4.2 s (SSPT), a mean increase 
of 5.8 s (95% CI, − 4.8 to 20.5) for exercise and 9.7 s (95% CI, 0.1 to 24.9) for manual therapy. Exercise provided more 
quality-adjusted life years than SSPT but was more expensive. At 4 months, significant changes above SSPT occurred 
in endurance and balance in manual therapy, and in endurance for those ≤ 70 years, in balance, mobility, and walking 
in exercise. 
Conclusions 
Adherence was problematic. Benefits at 4 months did not persist and at 12 months, we found no significant 
differences between treatments. There is inadequate evidence a short physiotherapy intervention of either 
manual therapy or home exercise provides long-term benefits, but arguably short-term benefits are valuable. 






Osteoporosis is a major public health problem that affects an estimated 3.2 million people in the 
United Kingdom (UK).1 It’s clinical importance lies in its association with bone fractures and their 
complications.2  Vertebral fractures are the most common osteoporotic fracture and are thought to 
affect at least 20% of the older population in the UK; thus around 1 in 5 people aged 50 years or 
more will have one or more osteoporotic vertebral fractures (OVF), with the incidence and 
prevalence increasing rapidly with age.2, 3  
 
OVFs result in increased mortality and significant morbidity, even if initially clinically asymptomatic.3- 
5 They are associated with back pain, fatigue, impaired mobility, depression, restricted activity and 
social participation and marked reductions in quality of life (QoL) that can persist for at least 18 
months post-fracture. 4-6  Vertebral fractures cause spinal deformity and alter spinal biomechanics, 
increasing the risk of subsequent vertebral fractures, hyperkyphosis, falls, non-vertebral fractures 
and restrictive lung disease.4,5,7  Osteoporosis and fragility fractures also present a substantial 
economic burden; with the cost of care in the UK estimated to rise from £4.4 billion pounds in 2010 
to approximately £5.5 billion pounds per year by 2025.1 
 
Physiotherapy is frequently recommended for patients with symptomatic OVFs  and can include a 
variety of exercise (strength, balance, postural exercises etc) and ‘hands-on’ manual therapies such 
as joint mobilisations and massage.1,7,9-11  In conjunction physiotherapists often provide substantial 
education e.g.; about osteoporosis, fall prevention strategies etc.12 However, evidence of 




costs of treatment.9  The aim of this trial was to assess the clinical and cost-effectiveness of three 
different physiotherapy approaches: manual therapy and exercise therapy for people with 




This was a multicentre, prospective, three-arm randomised controlled trial (RCT) with an adaptive 
design and blinded outcome assessment. It was a pragmatic trial, designed to measure the 
effectiveness of physiotherapy interventions in standard conditions. It took place in 21 National 
Health Service hospital outpatient physiotherapy centres across England. The trial was approved by 
the UK South Central Research Ethics Committee (REC: 12/SC/0411), and site-specific approvals were 
obtained. It was performed according to the published protocol, with no changes after the trial 




Potential participants were approached by staff at osteoporosis clinic visits or by mail, using 
electronic medical records from relevant radiology or primary care clinics to identify those with OVF.  
They were given an invitation letter and information pack and those interested were offered a 
research appointment.  Men and women aged 18 or over were eligible if they had a diagnosis of 
osteoporosis confirmed by radiograph or dual energy X-ray absorptiometry (DEXA) scan (T score -2.5 
SD below young adult mean at the lowest lumbar level), at least one previous OVF (confirmed on 




different times post-fracture, with different numbers of fractures and fracture locations were 
eligible.  They also had to be able to walk at least 10 metres, be able to exercise and participate in 
physiotherapy safely and, if female, to be post-menopausal. People with severe unstable 
cardiovascular or pulmonary disease, significant psychiatric or neurological conditions, bone loss 
secondary to other disease or medication, those who had undergone vertebroplasty, facet joint 
injection or physiotherapy in the previous 12 weeks were ineligible.  
 
Randomisation and masking 
Research clinicians confirmed participant eligibility, obtained written consent and conducted 
baseline assessment prior to randomisation to ensure allocation concealment.  The central 
telephone service at Warwick Clinical Trials Unit randomised participants between a program of 
exercise therapy, manual therapy or a single session of physiotherapy (SSPT) education and advice 
using a variable block randomisation schedule stratified by centre to control for confounding factors 
at local recruitment sites.  Research staff did not deliver treatments, and all staff conducting 
assessments and managing data were blinded to allocation group at all points. It was not possible to 
mask participants or physiotherapists providing interventions, but participants were asked not to 
disclose their allocated group to assessors.  
 
Outcome Assessments 
Clinical outcome assessment occurred at baseline, 4 and 12 months. The primary endpoint was 12 
months.  The co-primary outcomes were: 1)  QUALEFFO-41 : a disease specific health related QoL 
self-report questionnaire with 5 domains (pain, physical function, social function, general health 




the Timed Loaded Standing test (TLS) which records the time (in seconds) a person can stand with 
arms extended, shoulders flexed to 900 holding a 1kg weight.15 Holding time and test end relate to 
back muscle endurance.15,16  Secondary outcomes included thoracic kyphosis angle measured with a 
flexicurve ruler,17 standing balance evaluated using the Functional Reach test (FR), physical function 
and walking capacity assessed by the Short Physical Performance Battery (SPPB), a 6-minute walk 
test (6MW) and Physical Activity Scale for the Elderly (PASE), and falls incidence recorded with a 
monthly event calendar.18-21 Participants completed the EQ5D-5L and logged healthcare use in a 
standardised trial diary. Attendance and adverse events were recorded on standardised trial forms.  
 
Interventions 
Participants in manual therapy and exercise therapy were offered a 1-h assessment plus 6 individual 
outpatient physiotherapy sessions spread over 12 weeks with a specialist musculo-skeletal 
physiotherapist with at least 4-year post-graduate musculoskeletal experience. Interventions were 
individually tailored for each participant. Participants allocated SSPT were offered a single 1-h 
assessment, education, and advice session with a physiotherapist. See online Appendix 1 and 
published protocol for further detail.13 The comparator was single one-hour assessment, education 
and advice session with a physiotherapist. SSPT comprised general education about osteoporosis, 
vertebral fractures and strategies to reduce falls.  It covered lifestyle choices to promote bone health 
including general information about diet, regular weight-bearing exercise and physical activity. 
Information was consistent with osteoporosis clinical guidelines and information from the Royal 






Manual therapy included low velocity central posterior-anterior spinal mobilisations through the 
thoracic and/or lumbar spine, with vertebral level, grade (from grade 2 to 4) and number of 
repetitions selected individually. It also included soft tissue mobilisation, postural education 
including taping, and a home programme of passive stretches that promoted thoracic extension for 
up to 15 min daily13. 
 
Exercise therapy 
Exercise therapy consisted of a multi-component, progressed programme of balance, strength 
training concentrating on back extensor and postural muscles and functional weight-bearing exercise 
(walking, step-ups, etc.)13. Based on assessment, the physiotherapist selected exercises which were 
sufficiently challenging and could be performed effectively, safely, and comfortably from 
standardised, graded sets. Strength training intensity was set and monitored using the 0–10 rating of 
perceived exertion (RPE) scale at a participant-perceived moderate to somewhat hard level of effort 
(RPE level 3, 4)22. Balance exercises were progressed in a standard way, e.g. upper limb support to 
no upper limb support and eyes open to eyes closed. A pedometer was used to assess walking 
capacity, structure, and progress the walking programme3,22. Participants were asked to continue the 
exercise programme at home between clinic sessions aiming to include short sessions of exercise 
within daily life, aiming to achieve 45 min per day, 3 to 5 times a week depending on ability. 
Strategies were employed to promote adherence13. 
 
Single session of physiotherapy 
This consisted of general education about osteoporosis, vertebral fractures, and strategies to reduce 




regular weight-bearing exercise, and physical activity. Information was consistent with osteoporosis 
clinical guidelines and information from the Royal Osteoporosis Society (ROS, UK)2,11,23. The 
participants in the manual and exercise groups received general advice only. 
Physiotherapists received 4 h of training covering theoretical and practical application of the 
interventions. Therapists detailed the content of all treatment sessions in a treatment log and their 
usual clinical records. The research team reviewed treatment logs and visited each site to conduct 
fidelity checks, monitoring implementation against study protocols using a proforma and ensuring 
each therapist received a minimum of one quality control visit per treatment type that they gave. 
Further visits occurred based on the outcome of the initial visit. 
 
Sample size  
No formally established minimal clinically important difference (MCID) exists for QUALEFFO-41 or 
TLS tests. The sample size was calculated to detect a standardised effect of 0.4 in the QUALEFFO-41; 
at 80% power with an alpha of 0.05, which would require 180 to 200 participants in each group. We 
calculated between 540-600 participants were required, allowing for 10% drop-out.  
 
Statistical Analysis 
This was an adaptive trial, in which either active intervention arm could be dropped or the trial 
halted at an interim analysis. The interim analysis was guided by pre-specified rules using the 
estimated mean change in total QUALEFFO-41 from baseline to 4 months using data from 75 
participants per arm. If change from baseline in an intervention arm was no more than 0.5 points 
greater than SSPT, this arm would be dropped. Under this rule, both arms might be dropped, and 
the trial terminated. A change in one arm, more than 2 points higher than the other, would result in 




the better of the two intervention arms had a true standardised effect of 0.4. After accrual and 
follow-up of the first 75 participants, the rules were met for continuing as a three-arm trial. 
 
There was a pre-specified statistical analysis plan. Intention to treat analyses was performed, and 
participants were analysed in accordance with the group to which they were randomised. Baseline 
characteristics for participants in each arm were summarised by proportions for each level binary or 
categorical variables and means and standard deviations for continuous variables. We pre-specified 
that we would not impute missing data if the proportion of participants with missing data was less 
than 10% within each arm. The analyses of primary and secondary outcomes were adjusted for 
centre and baseline value of the outcome being considered. The analyses of primary outcomes were 
additionally adjusted to account for the adaptive design of the study and for the multiple compar-
isons arising from the two pairwise comparisons with SSPT using a closed testing procedure. We 
used an inverse normal combination function to combine individual and Dunnett-corrected p values 
obtained from treatment comparison adjusting for centre and baseline from the datasets from the 
two stages. No adjustment for multiplicity was made in analysing secondary endpoints. For the 
primary outcomes, unbiased estimates and confidence intervals correcting for the adaptive design 
and multiple testing were also obtained24. Results are presented as treatment effects with 95% 
confidence intervals and p values; statistical significance was defined as p = 0.05 (two-sided 5% 
significance level). 
 
Pre-planned sub-group analyses investigated the interaction between age ( 70 versus > 70 years), 
sex, baseline fracture status ( 2 versus > 2), and treatment allocation on primary outcomes adjusted 
for centre and baseline value. A pre-specified complier-average causal effect (CACE) analysis using 




outcomes using the number of sessions attended as an endogenous variable and adjusting for 
baseline and recruitment centre as exogenous variables. All analyses used R version 3.4.1 (www.R-
project. org) except the CACE analysis, which used STATASE 15.0 (www.stata.com). 
 
The cost-effectiveness analysis used EQ5D-5L and healthcare diary data collected from participants. 
The perspective was that of the NHS and personal social services (price year 2015/2016) and the 
outcome was incremental cost per quality-adjusted life year (QALY). The time horizon of the analysis 
was 1 year and costs and QALYs were not discounted. Missing resource use and EQ5D data were 
dealt with using multiple imputation where data were missing at random using predictive mean 
matching with five nearest neighbours. The difference in costs and QALYs was estimated with 
regression analysis, using a system of seemingly unrelated regressions. The probability of each 
intervention being the most cost-effective was estimated at a threshold of £20,000 per QALY 
gained25. Further details on the cost-effectiveness analysis are available in the online appendix, 
reported using the CHEERS checklist. 
 
Adverse events 
These were reported to the trial team and investigated further. They were classified through 
discussions with the local Principal Investigators, the Trial lead and one of the co-applicants Dr. 
Muhammad K Javaid, a Consultant in Metabolic Bone Medicine and reviewed by the trial Data 
Monitoring and Efficacy Committee (DMEC). 
 




Throughout, we were supported by the Royal Osteoporosis Society a UK charity, and a 
representative from this organisation was a co-applicant. Members of our local osteoporosis group 
and former patients with osteoporosis were also consulted when developing and refining trial 
interventions and materials. In a pilot phase at trial outset, a nested qualitative study explored the 
acceptability of the trial to participants. Another patient representative was a voting member of the 
trial steering committee and provided guidance. 
 
Results 
From September 2013 to September 2016, 1213 potentially eligible people were identified of which 
615 were enrolled. In total, 63/ 615 (10%) participants withdrew and a further 17/615 (3%) were 
non-contactable at 4 months, rising to 23/615 (4%) at 12 months (Figure 1). The most common 
reason for withdrawal was death or serious other illness: exercise (n=9), manual therapy (n=11), 
SSPT (2). Dissatisfaction with allocated arm was common in SSPT (n=7) but not in manual (n=1) or 
exercise therapy (n=0). Final data was collected in September 2017. 
 
Participants were aged from 42 to 97 years, mean age 72 (SD 9.1) years; 531/ 613 (86%) were 
women, 82/613 (13%) were men.  The mean lumbar spine DEXA T-score was -2.7 (SD 1.3), the 
average number of OVF was 2.5 (SD 1.9), most participants were hyperkyphotic and had 
substantially limited mobility and endurance (Table 1).  The groups were well-matched at baseline.  
Loss to follow up was highest in the exercise arm but less than 10% in all arms. Primary data at 12 
months was obtained for 529/615 (86%) participants for QUALEFFO-41 and 458/615 (75%) for TLS. 
Those without QUALEFFO-41 had slightly higher pain, those without TLS were more likely to have 






One participant withdrew on randomisation to SSPT, the remaining 195/196 (99%) attended. 
Exercise participants attended a mean 4.3 (SD 2.7) sessions; 143/216 (66%) partially complied 
(minimum 4 sessions) and 82/216 (38%) fully complied (7 sessions). Manual therapy participants 
attended a mean 5.03 (SD 2.6) sessions; 155/203 (76%) partially complied and 99/203 (49%) fully 
complied.  Fidelity checks showed no evidence of contamination (that participants crossed arms) 
and that intervention content was well delivered. Common barriers to attendance were other health 
problems, caring commitments, and transport difficulties. Healthcare diaries showed that 50/196 




A total of 85 adverse events were reported but there were no serious adverse events associated 
with the trial, according to the pre-specified criteria. In exercise, 24/216 (11%) participants reported 
26 events including 5 falls and 6 fragility fractures; in manual therapy, 34/203 (17%) participants 
reported 37 events with 6 falls and 9 fragility fractures, in SSPT 22/196 (11%) reported 22 events 
including 4 falls and 8 fragility fractures. Other events included the following: cardiovascular 
problems (stroke, tachycardia, etc.), respiratory and urinary tract infections, minor musculoskeletal 






At 12 months there was no statistically significant effect observed from either intervention over 
SSPT on either primary outcome.  Sub-group and CACE analyses showed no significant differences.  
Within groups total QUALEFFO-41 scores improved slightly relative to baseline and TLS endurance 
increased by a mean 9.8s, or 20% (exercise), a mean 13.6s, or 28% (manual therapy) and 4.2s or 8% 
(SSPT).   Whilst these changes were clinically significant, there were no statistically significant 
findings between the groups. Improvements in thoracic kyphosis were largest in the manual and 
exercise therapy groups over 12-months (Table 2). Mean kyphosis reduction at 12 months was − 6.9° 
(exercise), − 4.6° (manual therapy), and − 2.7° (SSPT), changes that are recognised as clinically 
significant, but there were no statistically significant differences between the groups. 
 
Although there was no statistically or clinically significant difference in outcomes at 12 months, 
there was some difference in the early pattern of response, measured at 4 months, with clinically 
and statistically significant improvements in the primary outcome of TLS endurance in manual 
therapy compared to SSPT and in those 70 years or younger in exercise therapy. The CACE analysis 
suggested improvements due to manual therapy increased with the number of sessions attended. In 
manual therapy compared with SSPT, TLS increased by a mean of 1.95 s (95% CI 0.45 to 3.44), p = 
0.01 for each session attended. In-home exercise, TLS increased by a mean of 1.52 (95% CI − 0.23 to 
3.27), p = 0.09 for each session attended. At this point, there were also significant improvements in 
balance (FR) in both exercise and manual therapy above SSPT and significant improvements in 
functional mobility (SPPB and 6 MW) above SSPT in exercise therapy (Tables 2 and 3). 
 
Cost-effectiveness 
Exercise therapy was more effective (0.002 QALYs, 95% CI − 0.020 to 0.025) but more costly than 
SSPT (£206, 95% CI − £228 to £641) whereas manual therapy was less effective (− 0.014, 95% CI − 




Online appendix). Using a threshold of £20,000 per QALY gained, the most cost-effective option was 
SSPT with a probability of 69% (Table 4). Sub-group analyses indicated exercise therapy to be cost-
effective for those aged 70 years or younger (£12,310 per QALY gained) but not for those over 70 
(52% probability). Full data on resource use, costs, EQ5D utility, and cost-effectiveness analysis will 




Overall, at 12 months, this trial found no statistically significant differences between the three 
treatments and SSPT to be the most cost-effective option. All of the treatments demonstrated some 
degree of benefit that would be consistent with clinically important changes, but overall, there was 
no significant difference between them. 
 
The reduction in thoracic kyphosis in the exercise and manual therapy arms at 12 months was of a 
level judged clinically important in other trials.10,26 Thoracic kyphosis usually progresses with age and 
hyperkyphosis is associated with excess morbidity and mortality, so even small reductions are 
valuable if sustained.8,10,26,27 Significant differences in back muscle endurance as measured by timed 
loaded stand were seen early after treatment but by 12 months, there was no significant difference 
between the groups, although modest increases persisted. Back muscle fatigue and difficulty 
carrying out tasks in standing due to fatigue are key problems for people with OVF and chronic back 
pain that affect QoL15,28. Back muscle weakness is also correlated negatively with kyphosis angle, 
associated with hyperkyphosis and an increased risk of fractures29–31. Most participants had poor 
endurance on trial entry,15,16 and deterioration or no improvement would be expected in this 





The sub-group analysis highlighted improvements in endurance were experienced primarily by those 
70 years or younger. Ageing is associated with increased osteoporosis severity, number of 
comorbidities and frailty, and neuro-muscular changes such as sarcopenia. These factors may 
compound problems due to spinal pathology for older people with osteoporosis.28 Younger 
participants may have had more capacity to improve and/or found home exercise and treatment 
attendance easier. 
 
At 4 months, balance improved significantly in both intervention arms above SSPT. A 1-cm increase 
in FR in older adults is thought clinically relevant;32 mean changes greater than 2 cm occurred in 
both arms, the larger in exercise therapy potentially due to combined balance and strength training. 
In addition, significant, clinically relevant gains in functional mobility and walking capacity were seen 
in exercise therapy33. By 12 months, improvements in balance and mobility in intervention groups 
reduced in size, gains were seen in SSPT, and differences were no longer significant. 
 
Comparison with other studies 
Over the trial there were no significant differences in QoL between groups as measured by total 
QUALEFFO-41 or EQ5D-5L.  However, the improvement we saw within exercise therapy was of 
similar magnitude to significant findings in a trial without an active comparator.12  Evstigneeva et al. 
(2016) reported larger benefits immediately after a 12-month (104 session) intervention, but here 
QoL deteriorated in the no-intervention control, emphasising effects and no longer follow-up occurs. 
35  Five other RCTs report no significant change in total QUALEFFO-41 between groups after 
treatment, although one shows significant change in subscales and one in an accompanying generic 




severity to ours, found QoL improved after 6 months of home-based physiotherapy and exercise and 
a further 2 RCTs of exercise interventions in women with and without OVFs demonstrate 
improvements in QoL post-treatment. 40-42 These studies use other osteoporosis-specific QoL 
instruments. 40-42   Although QUALEFFO-41 is the most common measure, whether it is the best 
instrument for evaluating change due to rehabilitation is unclear.43 
 
Increased back strength or endurance immediately after physiotherapy has been observed in other 
RCTs in this population.39, 41, 44, 45  Improved balance immediately after treatment is also reported. 12, 
35  Bergland et al. (2011) found improvements in FR of a comparable magnitude after a 12 week (24 
session) exercise class intervention.12  Improvements have been associated with reduced fear of 
falling,46 but as in our trial not with significant reductions in falls at 1 year. 37, 46  The two other studies 
that conduct longer follow-up found, like us, when supervised intervention ceased differences 
between groups diminished and at 12 months changes were not significant.12, 44 
 
Consistent with our trial, three previous RCTs of exercise therapy for people with OVFs have 
demonstrated significant improvements in functional mobility post-treatment. 12, 35, 46 In contrast, 
Papaioannou et al. (2003) found no significant improvement.40  Whether exercise dose was sufficient 
is uncertain, adherence to 3 days/ week of home exercise was 62% (23/37 women) at 6 months, 
decreasing to 46% (17/37) at 12 months.40 In our trial, mobility gains reduced and were no longer 
significant at 12 months.  Unlike us, Bergland et al. (2011) found gains persisted at 12 months.12 
Here, exercise dose appears higher, 75% (34/45 women) attended at least 79% (19) of 24 classes, 
and the group format may have provided additional benefits.12  
 




This trial is the largest RCT to assess physiotherapy for people with OVFs to date and the first to 
provide information about cost effectiveness.  Most participants had severe osteoporosis; 
characterised by multiple OVFs, hyperkyphosis, back pain, poor back muscle endurance and limited 
exercise capacity.   The trial was well conducted and pragmatic, designed to test interventions 
deliverable in routine practice.  Contrary to most previous studies it evaluated longer term effects of 
interventions. 
 
However, our intervention was potentially too low intensity to sustain improvements. Determining 
the intervention dose was challenging, models of treatment delivery in RCTs in similar populations 
vary widely, e.g. from individual sessions plus daily home-based self-directed exercise, to 104 class 
sessions over 12 months34, 40. Although 7 sessions across 12 weeks seem limited when compared 
with prolonged exercise class interventions, previous trials with individual sessions and home 
programmes reported benefits, and individual sessions are required for manual treatments.10, 12, 34–41, 
43, 44 Our interventions resembled these trials and tested a common model of service delivery, i.e. 
outpatient physiotherapy rehabilitation plus a self-directed home programme that was feasible to 
deliver within a publicly funded healthcare system. 
 
An issue specific to the cost-effectiveness analysis was the missing EQ5D and patient diary data. 
Complete EQ5D-5L and cost data was available for only 242/613 (40%) of participants. However, the 
sensitivity analysis explored the impact of different imputation models and SSPT remained the most 





Our comparator was education by a physiotherapist and 25% (50/196) participants in SSPT sourced 
additional physiotherapy of some kind outside of the trial. Our results show that unlike trials with no 
treatment comparators that report deterioration, small gains were seen in SSPT in most outcomes, 
against the expected disease course and suggestive of static success. These gains may represent a 
placebo response, educational benefits, or the effect of physiotherapy treatment sourced outside of 
the trial but reduced between-group difference. Furthermore, most participants did not receive the 
planned intervention intensity, potentially resulting in smaller treatment effects in both intervention 
groups. This was highlighted by the CACE analysis which suggested those who attended more 
sessions experienced greater benefits. Other studies of both class and individual interventions have 
also reported problems with compliance10, 38, 43, 44, 46. Direct comparisons are complex as compliance 
is defined and measured in varied ways across studies. For example, Bautmans et al. (2010) report 
15/29 (52%) participants comply, attending 50% (9/18) physiotherapy sessions over 12 weeks, Gold 
et al. (2004) noted 94 participants attended an average of 58% (70/120) exercise classes, or see 
Papaioannou et al. (2003) (discussed above)10, 38, 43. Multiple factors affect treatment adherence in 
older people with chronic diseases such as osteoporosis; problems with transport, caring 
commitments, and ill-health were common barriers to attendance reported by participants in our 
trial, but other personal and programme characteristics might be influential47. Overall, these factors 
potentially resulted in smaller effects in the intervention groups and magnified effects in SSPT, 
exposing the trial to the risk that intervention effects were lost or underestimated. 
 
Further research 
Further research is important into factors that assist compliance, alongside investigations that 




the responsiveness of the QUALEFFO-41 to rehabilitation interventions compared to other 
osteoporosis QoL instruments and to establish a formal MCID. 
 
Conclusions and implications 
The key messages are that at the main endpoint at one year the trial did not find significant 
differences between the three treatments in terms of effectiveness. However, several measures 
showed benefit at 4-months and some benefits persisted at 12-months. Whilst there is not adequate 
evidence to support manual or exercise therapy for long-term benefit it is arguable that short-term 
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Table 1: Baseline Participant Characteristics  
 Exercise Therapy  Manual Therapy  SSPT 
 
No. (%) female participants 185 (85.6%) (n=216)   173 (85.6%) (n=202)   173 (88.7%) (n=195) 
Age mean (SD), y. 72.2 (8.4) (n=216) 72.4 (9.3) (n=203) 71.9 (9.6) (n=196) 
Height mean (SD), cm 156.4 (20.6) (n=216) 159.1 (8.7) (n=201) 155.6 (20.8) (n=195) 
Weight mean (SD), kg 64.3 (16.4) (n=216) 64.1 (14.4) (n=202) 62.9 (10.9) (n=195) 
DEXA lumbar T score, mean (SD) -2.6 (1.5) (n=162) -2.7 (1.2) (n=162) -2.8 (1.3) (n=147) 
No. spinal fractures, mean (SD) 2.7 (1.8) (n=196) 2.4 (1.8) (n=187) 2.5 (2.1) (n=169) 
No. non-spinal fractures, mean (SD) 0.2 (0.4) (n=194) 0.2 (0.4) (n=184) 0.1 (0.3) (n=177) 
No. (%) back pain last 2 weeks 209 (96.8%) (n=216) 194 (96.0%) (n=202) 188 (96.4%) (n=195) 
No. (%) back pain today 157 (72.7%) (n=216) 133 (65.8%) (n=202) 128 (66.0%) (n=194) 
NPRS back pain, mean SD (0 -10) 4.8 (2.2) (n=156) 4.5 (2.1) (n=133) 4.6 (2.1) (n=127) 
No. falls in last year, mean (SD) 0.8 (2.3) (n=214) 0.7 (1.4) (n=201) 0.6 (1.0) (n=192) 
No. fallers (%) in category 1(a)  1 (0.5%) (n=207) 1 (0.5%) (n=193) 0 (0.0%) (n=188) 
                              category 2 19 (9.2%) (n=207) 14 (7.3%) (n=193) 8 (4.3%) (n=188) 
                              category 3 187 (90.3%) (n=207) 178 (92.2%) (n=193) 180 (95.7%) (n=188) 
QUALEFFO-41, mean (SD) 39.9 (16.0) (n=214) 37.1 (14.9) (n=200) 38.1 (15.9) (n=195) 
TLS, mean (SD), s 48.6 (54.5) (n=210) 47.9 (51.7) (n=197) 52.4 (58.7) (n=193) 
PASE, mean (SD) 109.7 (89.7) (n=191) 115.6 (81.3) (n=182) 106.9 (71.2) (n=165) 
Thoracic kyphosis mean (SD), deg. 51.2 (34.8) (n=213) 48.6 (22.4) (n=199) 49.1 (40.6) (n=194) 
SPPB, mean (SD) 8.3 (2.1) (n=200) 8.6 (2.1) (n=185) 8.4 (2.2) (n=184) 
Functional reach mean (SD), cm 23.5 (8.8) (n=216) 23.4 (10.5) (n=201) 23.8 (9.8) (n=195) 
6 MWT, mean (SD), m 295.4 (128.0) (n=216) 304.2 (135.3) (n=201) 313.4(129.4) (n=194) 
Abbreviations: DEXA, dual energy X-ray absorptiometry, NPRS, numeric pain rating scale, TLS, timed loaded 
standing test, PASE, physical activity scale for the elderly, SPPB, short physical performance battery, 6MWT, 
6-minute walk test, (a)Participant falls 1 = Frequently (≥ once a week), 2 = Occasionally (≤ once a month), 3 











Exercise Therapy Manual Therapy  SSPT 
Mean (SD) change 
from baseline 
Change relative to 
control adjusted for 
centre and baseline 
(95% CI) 
P value Mean (SD) change 
from baseline 
Change relative to 
control adjusted for 
centre and baseline 
(95% CI) 




total (0-100) * 
4 mo. -2.16 (8.40) (n=180) -1.23 (-2.84,0.37) p=0.13 -0.55 (8.17) (n=185) 0.27 (-1.32,1.86)  p=0.74 -0.87 (7.05) (n=173) 
12 mo. -1.31 (9.97) (n=176) -0.23 (-3.20, 1.59)+ p=1.00+ -0.15(10.81) (n=181) 1.35 (-1.76, 2.93)+ p=0.74+ -1.18(8.89) (n=172) 
TLS s 4 mo. 7.42 (47.90) (n=162) 7.46 (-1.43,16.35) p=0.10 11.80 (40.27) (n=171) 10.56 (2.22,18.90)  p=0.01 -0.58 (40.90) (n=161) 




4 mo. -7.76 (18.51) (n=180) -3.57 (-7.39, 0.25)  p=0.07 -5.58 (21.41) (n=182) -2.54 (-6.56, 1.48) p=0.27 -3.77 (19.13) (n=173) 
12 mo. -9.07 (22.88) (n=176) -2.80 (-7.07, 1.46) p=0.19 -6.75 (22.98) (n=180) -1.03 (-5.22, 3.17)  p=0.63 -6.25 (18.39) (n=172) 
Physical 
function 
4 mo. -2.81 (9.45) (n=180) -1.02 (-2.83, 0.80)  p=0.27 -0.89 (8.54) (n=185) 0.73 (-0.99, 2.45)  p=0.41 -1.66 (8.35) (n=173) 
12 mo. -0.70 (11.41) (n=176) 0.18 (-2.04, 2.41)  p=0.87 1.10 (11.56) (n=181) 1.78 (-0.48, 4.04)  p=0.12 -0.90 (10.16) (n=172) 
Social function 4 mo. -3.22 (14.32) (n=180) -2.71 (-5.46, 0.03)  p=0.05 -0.83 (15.75) (n=185) -0.98 (-3.86, 1.90) p=0.41 -0.10 (13.30) (n=172) 
12 mo. -1.65 (16.09) (n=175) -0.66 (-3.68, 2.37)  p=0.67 0.02 (17.26) (n=181) -0.11 (-3.31, 3.08)  p=0.94 -0.45 (16.11) (n=172 
General health 
perception 
4 mo. -1.99 (15.48) (n=180) -1.07 (-4.01, 1.88)  p=0.48 0.43 (15.09) (n=184) 0.65 (-2.17, 3.48) p=0.65 0.10 (13.45) (n=173) 
12 mo. -0.17 (18.83) (n=175) -0.06 (-3.61, 3.50)  p=0.97 1.00 (18.15) (n=180) 0.07 (-3.33, 3.47)  p=0.97 1.03 (16.09) (n=170) 
Mental health 4 mo. -0.23 (10.32) (n=180) 1.56 (-0.59, 3.71)  p=0.16 -0.84 (10.50) (n=184) 0.96 (-1.17, 3.09)  p=0.37 -2.06 (11.27) (n=173) 
12 mo. 1.45 (11.69) (n=174) 1.65 (-0.81, 4.10)  p=0.19 0.22 (13.14) (n=180) 0.18 (-2.35, 2.71)  p=0.89 -0.37 (12.56) (n=171) 
Thoracic 
Kyphosis* deg. 
4 mo. -4.21 (40.63) (n=170) 0.82 (-3.27,4.90)  p=0.70 -2.58 (9.31) (n=173) -0.71 (-3.96,2.55)  p=0.67 -3.26 (40.33) (n=167) 
12 mo. -6.88 (31.66) (n=152) -2.24 (-6.40,1.92)  p=0.29 -4.63 (22.28) (n=156) -3.02 (-8.14,2.10)  p=0.25 -2.73 (49.58) (n=167) 
PASE 4 mo. 10.26 (54.58) (n=133) 0.9 (-13.58,15.48)  p=0.90 9.38 (86.20) (n=136) 1.67 (-16.78,20.12)  p=0.86 8.02 (66.41 (n=125) 
12 mo. 9.72 (63.64) (n=116) 6.33 (-8.40,21.06)  p=0.40 4.22 (67.02) (n=127) 1.56 (-12.92,16.04) P=0.83 6.75 (57.58) (n=122) 
SPPB 4 mo. 0.81 (1.72) (n=152) 0.45 (0.11,0.79)  p=0.01 0.31 (1.51) (n=157) -0.03 (-0.35,0.30)  p=0.88 0.39 (1.57) (n=150) 
12 mo. 0.66 (1.78) (n=134) 0.18 (-0.21,0.57)  p=0.36 0.15 (1.49) (n=141) -0.19 (-0.54,0.16)  p=0.28 0.47 (1.75) (n=149) 
Functional 
Reach cm 
4 mo. 1.28 (9.19) (n=170) 2.43 (0.71,4.16)  p=0.01 1.53 (9.56) (n=177) 2.11 (0.57,3.64)  p=0.01 -0.80 (9.85) (n=168) 
12 mo. 0.26 (8.57) (n=152) 1.02 (-0.96,3.01)  p=0.31 1.18 (13.00) (n=155) 0.54 (-1.65,2.73)  p=0.63 -0.21 (12.72) (n=165) 
No. Falls in last 
year (a)  
4 mo.  -0.08 (-0.46,0.29)  p=0.66  -0.05 (-0.41,0.31)  p=0.78  




6MWT m 4 mo. 28.09 (102.5) (n=167) 26.09 (6.58,45.60)  p=0.01 16.73 (90.18) (n=174) 16.16 (-1.76,34.09)  p=0.08 -1.73 (84.71) (n=166) 
12 mo. 19.1 (103.77) (n=150) 6.83 (-13.08, 26.74)  p=0.50 20.19 (87.45) (n=157) 12.02 (-6.46,30.50)  p=0.20 7.16 (88.48) (n=164) 
*A negative change corresponds to a better outcome, a) estimate reported is log-risk ratio 




Table 3: Sub-group analyses 






to SSPT adjusted 
for centre and 
baseline (95% CI, 
p-value)  
P value for 
interaction 
Change relative 
to SSPT adjusted 
for centre and 
baseline (95% CI, 
p-value) 
P value for 
interaction 
QUALEFFO-41 at 12 months  
Female  -0.41 (-2.49, 1.66) 
p=0.695  
0.357  0.87 (-1.27, 3.00) 
p=0.428  
0.985  (154;155;154) 
Male 3.61 (-2.09, 9.30) 
p=0.225 
 0.42 (-7.69, 8.54) 
p=0.919 
 (22;26;18) 
Age ≤ 70 -0.00 (-3.22, 3.22) 
p=1 
0.834  -0.36 (-3.92, 
3.20) p=0.842  
0.937  (68;66;68)  
Age ≥7 0 -0.58 (-3.13, 1.97) 
p=0.656   
 0.83 (-1.73, 3.38) 
p=0.527   
 (108;115;104) 
≤ 2 spinal 
fractures 
-0.25 (-2.49, 2.00) 
p=0.829  
0.975  1.39 (-1.17, 3.95) 
p=0.288  
0.275  (77;95;86) 
≥ 2 spinal 
fractures 
-3.45 (-7.65, 0.74) 
p=0.111 
 0.13 (-4.75, 5.01) 
p=0.959 
 (52;49;49) 




0.892 4.50 (-5.64, 
14.64) p=0.384 
0.112 (130,130,141) 
Male -5.91 (-51.19, 
39.37) p=0.801 
 33.77 (-7.27, 
74.82) p=0.119 
 (18;23;16) 







Age ≥ 70 2.07 (-
10.99,15.14) 
p=0.756 
 8.34 (-3.36, 
20.04) p=0.164 
 (90;94;93) 




0.254 4.41 (-9.43,18.25) 
p=0.533 
0.563 (76;93;81) 





 11.41 (-6.19, 
29.02) p=0.207 
 (62;53;66) 
QUALEFFO-41 at 4 months 
Female -1.43 (-3.15, 0.29) 
p=0.103 
0.531 -0.18 (-1.79, 
1.43) p=0.827 
0.138 (159,158,156) 
Male 0.15 (-4.65, 4.96) 
p=0.950 
 4.08 (-3.23, 
11.40) p=0.283 
 (21;27;17) 
Age ≤ 70 -2.01 (-4.67, 0.65) 
p=0.141 
0.134 -2.12 (-4.89, 
0.64) p=0.135 
0.204 (69;70;67) 
Age ≥ 70 -0.91 (-3.06, 1.24) 
p=0.409 
 1.32 (-0.71, 3.34) 
p=0.204 
 (111;115;106) 
≤ 2 spinal 
fractures 
-1.04 (-2.99, 0.92) 
p=0.301 






≥ 2 spinal 
fractures 
-1.38 (-4.41, 1.64) 
p=0.373 
 1.39 (-1.76, 4.55) 
p=0.389 
 (62;58;53) 
TLS at 4 months 
Female 7.05 (-2.52,16.61) 
p=0.150 
















Age ≥ 70 0.15 (-
11.45,11,75) 
p=0.980 
 2.28 (-8.26,12.82) 
p=0.672 
 (97;109;97) 




0.195 6.97 (-4.78,18.73) 
p=0.247 
0.294 (78;99;84) 













Table 4. Cost-effectiveness results using NHS and social services perspective at 12 months 
  Complete case 
analysis (n=242)  
Multiple imputation of 
costs and EQ5D* 
(n=613) 
Exercise vs SSPT    
Difference in costs (£) Mean 536 216 
SE 367 224 
95% CI -183 to 1255 -223 to 655 
Difference in QALYs adjusted for 
baseline EQ-5D 
Mean  0.017 0.002 
SE 0.015 0.011 
95%CI -0.013 to 0.048 -0.020 to 0.025 
ICER £/QALY 31,098 100,525 
Probability of being CE at £20,000 
per QALY 
 36% 31% 
    
Manual vs SSPT    
Difference in costs (£) Mean -72 244 
SE 361 224 
95% CI -780 to 635 -195 to 683 
Difference in QALYs adjusted for 
baseline EQ-5D 
Mean  -0.011 -0.014 
SE 0.015 0.012 
95%CI -0.041 to 0.019 -0.036 to 0.009 
ICER £/QALY 6,710 (not cost-
effective) 
Dominated 
Probability of being CE at £20,000 
per QALY 
 39% 7% 
*Multiple imputation by intervention with predictive mean matching using baseline covariates: female, age at 
randomisation, EQ5D score at baseline, mobility (walking distance), recruitment site, falls in previous year, 





Figure 1: PROVE Study Consolidated Standards of Reporting Trials flow diagram 
 
 
